Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

CeNeRx Initiates Phase II Trial of TriRimaâ„¢ as Monotherapy in Treatment Resistant Depression

January 6, 2011 By Bio-Medicine.Org

RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2011 /PRNewswire/ —
CeNeRx BioPharma, Inc., today reported that it has initiated a
Phase II trial of its new formulation of TriRima™, the
company’s novel antidepressant in development as monotherapy for
treatment resistant depression.  CeNeRx also announced that it
will be presenting atBiotech Showcase™ 2011
onTuesday, January 11, 2011 at 11:00 AM PST.

TriRima is a member of a novel class of drugs known as
RIMAs, or reversible and selective inhibitors of monoamine oxidase
A (MAO-A).  MAO inhibitors achieve superior “triple-action”
antidepressant efficacy by elevating the levels of all three of the
key neurotransmitters that positively affect mood.  However,
older MAO inhibitors have been limited by their potential to cause
serious cardiovascular side effects when foods containing the
naturally occurring substance tyramine are consumed.  

TriRima is designed to achieve the efficacy of the MAO
inhibitor class while reducing or eliminating the risk of these
food-associated effects.  In a recently reported “tyramine
challenge” study, subjects receiving the new formulation of
TriRima showed no signs of any negative effects, even after
being exposed to large amounts of tyramine.  These positive
results further confirmed the good safety profile demonstrated by
TriRima in Phase I studies.

The Phase II trial is a double blind, placebo-controlled study
designed to assess the efficacy of TriRima administered
twice daily as monotherapy in patients with treatment resistant
depression.  Secondary objectives include evaluating TriRima’s
safety and tolerability and assessing its pharmacokinetic profile.
 CeNeRx expects to enroll 360 patients in the study, which is
being conducted at multiple centers in the U.S.

“We are eager to test the efficacy of our promising new
formulation of TriRima

‘/>”/>

SOURCE

Related Articles Read More >

Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech